| Document Date: 2014-11-03 11:26:18
Open Document File Size: 45,28 KBShare Result on Facebook
City Osaka / Glasgow / London / / Company ViiV Healthcare / Shionogi & Co. Ltd. / Corporate Communications Shionogi & Co. Ltd. / / Country United Kingdom / Japan / / Event FDA Phase / / / IndustryTerm foreign healthcare reforms / with respect to product / / MedicalCondition HIV Infection / / MedicalTreatment Drug Therapy / / Organization International Congress / / Person Isao Teshirogi / Dominique Limet / / / Position President & CEO / Chief Executive Officer / / Product Integrase Inhibitor / SPRING-2 / /
SocialTag |
Data from VIKING-3 Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, November 14, Shionogi & Co., Ltd. (Head Office: Osaka; President & C